Commercial

FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis

May 15, 2018

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age and older. Actemra can be given alone or […]

Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC

May 15, 2018

Basel, Switzerland, May 15, 2018 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Hikma Pharmaceuticals LLC has launched Basilea’s hospital antibiotic Zevtera® (ceftobiprole) in Saudi Arabia. Adesh Kaul, Chief Corporate Development Officer, said: “We are very pleased with the launch of Zevtera in Saudi Arabia. This is the first launch by our […]

UTILITY therapeutics signs license agreement with LEO Pharma A/S for US rights to mecillinam and pivmecillinam

May 15, 2018

London, UK. 15th May 2018 – UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercialising antibiotics in the US, today announces the signature of an exclusive license agreement for the antibiotics mecillinam and pivmecillinam with LEO Pharma A/S. The license agreement provides UTILITY with exclusive access to LEO Pharma’s […]

Envision Pharma Group announces the successful implementation of iEnvision to connect and support Otsuka’s medical affairs activities

May 15, 2018

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) has completed the first phase of implementation of the iEnvision medical affairs platform developed by Envision Technology Solutions, part of Envision Pharma Group. iEnvision is a web-based software platform specifically designed and developed to support multiple medical affairs-related programs of activity. Otsuka is deploying iEnvision to manage several […]

Big data study by Elsevier probes how well animal studies predict human safety

May 15, 2018

Large-scale study of more than 1.6 million adverse events reported to the FDA and EMA analyses predictivity of animal-human relationship in relation to patient safety A big data analysis conducted by global information analytics business, Elsevier, has evaluated the ability of animal studies to predict human safety. The statistical study examined the consistency between preclinical […]

TraceLink Adds Industry Visionaries to Discuss Machine Learning, Artificial Intelligence, Big Data and Patient Engagement at FutureLink Munich

May 15, 2018

NORTH READING, Mass. (May 14, 2018)—TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced the latest keynote speakers for its upcoming FutureLink Munich conference to be held June 5-7, 2018.  Confirmed speakers include industry and academic thought-leaders: Professor […]

Achema: New answers for the digital pharma factory of the future by Werum IT Solutions

May 15, 2018

Werum presents innovations for PAS-X MES / A world first: Pharma MES in the Cloud / Werum’s stand in hall 11.1-A75 Lüneburg, Germany, 15 May 2018 – Digitization of processes, integration of software and equipment, operating concepts for the pharmaceutical shop floor or big data and analysis – Werum IT Solutions will present new answers […]

What’s the Fix? Conference Livestream May 17, 2018

May 14, 2018

Patient stories, solutions, and health care hacks shared at second annual free online event AUSTIN, TX. (May 14, 2018) – What’s the Fix?, the only health care event to feature patients who have circumvented the system to overcome obstacles and drive change, today announced its innovative livestream experience for all digital attendees of the second […]

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

May 14, 2018

The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients. “For the first time, we have an FDA-approved treatment specifically for children and adolescents with […]

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

May 14, 2018

Basel, May 11, 2018 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis (RMS), making it the first disease-modifying therapy indicated for these patients[2]. This approval expands […]

Huntington’s Disease Therapeutics Market to Grow Owing to Introduction Of Innovative Drugs: Radiant Insights, Inc.

May 14, 2018

SAN FRANCISCO, May 14, 2018 /PRNewswire/ —   Global huntington’s disease therapeutics market is anticipated to grow at a steady CAGR in future. Hungtington’s disease (HD) is mainly prevalent in adults which is chronic and progressively neurodegenerative disease by nature. Medically, it is characterized by choreic involuntary movements followed by psychiatric, psychological and intellectual disorders […]

FEEDBACK